CIK: 0002106181
Total reported value
$141.3M
Reporting period: 2026-03-31 · Number of holdings: 27
Kalehua Capital Management LLC disclosed 27 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $141.3M and a quarterly turnover rate of 52.4%.
Browse other institutions with $100M to $1B AUMBrowse other institutions starting with "K"
Sector classification currently covers about 0% of this portfolio's disclosed value; the remainder includes holdings (e.g. unmapped tickers, options, or other security types) not yet covered by our sector mapping.
Trim BOXX
-5.4% -$1.2M
Add SRZN
0.0% $9.3M
Trim XFOR
0.0% $484.0K
Trim SION
0.0% -$206.9K
Trim CMPS
0.0% -$1.1M
Trim SEPN
0.0% -$749.0K
Showing top 25 holdings (of 27 total)
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | BOXX | Alpha Architect 1-3 Mnth Box | ETF-Other | 17.96% | -8.31% | -5.42% | |
| 2 | XFOR | X4 Pharmaceuticals INC | Stock-Other | 10.88% | -3.85% | — | |
| 3 | SRZN | Surrozen INC | Stock-Other | 7.94% | +6.07% | — | |
| 4 | MANE | Veradermics INC | Stock-Other | 6.51% | +6.51% | NEW | |
| 5 | RLAY | Relay Therapeutics INC | Stock-Other | 6.35% | -1.19% | — | |
| 6 | SION | Sionna Therapeutics INC | Stock-Other | 5.59% | -2.43% | — | |
| 7 | ACRS | Aclaris Therapeutics INC | Stock-Other | 4.86% | +4.86% | NEW | |
| 8 | IKT | Inhibikase Therapeutics INC | Stock-Other | 4.54% | +0.99% | +118.39% | |
| 9 | ORKA | Oruka Therapeutics INC | Stock-Other | 4.11% | +0.56% | — | |
| 10 | PHVS | Pharvaris N.V. | Stock-Other | 3.97% | -1.49% | — | |
| 11 | QURE | uniQure N.V. | Stock-Other | 3.37% | +3.37% | NEW | |
| 12 | SEPN | Septerna INC | Stock-Other | 3.31% | -2.05% | — | |
| 13 | CMPS | Compass Pathways PLC | Stock-Other | 3.21% | -2.38% | — | |
| 14 | LONA | Leonabio INC | Stock-Other | 2.86% | -0.09% | — | |
| 15 | DMRA | Damora Therapeutics INC | Stock-Other | 2.55% | +2.55% | NEW | |
| 16 | GOSS | Gossamer Bio INC | Stock-Other | 2.38% | +2.38% | NEW | |
| 17 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 2.32% | +0.03% | — | |
| 18 | TYRA | Tyra Biosciences INC | Stock-Other | 2.02% | +0.08% | — | |
| 19 | PEPG | Pepgen INC | Stock-Other | 1.25% | +1.25% | NEW | |
| 20 | TIL | Instil Bio INC | Stock-Other | 1.07% | +1.07% | NEW | |
| 21 | TNYA | Tenaya Therapeutics INC | Stock-Other | 0.98% | -0.43% | — | |
| 22 | KRRO | Korro Bio INC | Stock-Other | 0.88% | +0.88% | NEW | |
| 23 | KLRS | Kalaris Therapeutics INC | Stock-Other | 0.55% | -0.62% | -3.08% | |
| 24 | DMAC | Diamedica Therapeutics INC | Stock-Other | 0.30% | -0.45% | -34.47% | |
| 25 | LOOP | Loop Industries INC | Stock-Other | 0.26% | +0.26% | NEW |
Performance for Q3 2026
+8%
Performance Last 4 Quarters
+14.9%
Based on 5 months of available history
Based on 78% of reported portfolio value with available pricing
Not enough sector-mapped data yet
Kalehua Capital Management LLC's most significant position changes for 2026-03-31: New buy: Veradermics INC (MANE); New buy: Aclaris Therapeutics INC (ACRS); New buy: uniQure N.V. (QURE); New buy: Damora Therapeutics INC (DMRA); Sold out: Allogene Therapeutics INC (ALLO).
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | SRZN | Surrozen INC | +6.1% | — | Unchanged |
| 2 | IKT | Inhibikase Therapeutics INC | +1% | +118.39% | Add |
| 3 | ORKA | Oruka Therapeutics INC | +0.6% | — | Unchanged |
| 4 | TYRA | Tyra Biosciences INC | +0.1% | — | Unchanged |
| 5 | MLTX | Moonlake Immunotherapeutics | 0% | — | Unchanged |
| 6 | LONA | Leonabio INC | -0.1% | — | Unchanged |
| 7 | TNYA | Tenaya Therapeutics INC | -0.4% | — | Unchanged |
| 8 | DMAC | Diamedica Therapeutics INC | -0.5% | -34.47% | Trim |
| 9 | KLRS | Kalaris Therapeutics INC | -0.6% | -3.08% | Trim |
| 10 | RLAY | Relay Therapeutics INC | -1.2% | — | Unchanged |
| 11 | PHVS | Pharvaris N.V. | -1.5% | — | Unchanged |
| 12 | SEPN | Septerna INC | -2.1% | — | Unchanged |
| 13 | CMPS | Compass Pathways PLC | -2.4% | — | Unchanged |
| 14 | SION | Sionna Therapeutics INC | -2.4% | — | Unchanged |
| 15 | XFOR | X4 Pharmaceuticals INC | -3.9% | — | Unchanged |
| 16 | BOXX | Alpha Architect 1-3 Mnth Box | -8.3% | -5.42% | Trim |
| 17 | MANE | Veradermics INC | — | NEW | New buy |
| 18 | ACRS | Aclaris Therapeutics INC | — | NEW | New buy |
| 19 | QURE | uniQure N.V. | — | NEW | New buy |
| 20 | DMRA | Damora Therapeutics INC | — | NEW | New buy |
| 21 | ALLO | Allogene Therapeutics INC | — | EXIT | Sold out |
| 22 | GOSS | Gossamer Bio INC | — | NEW | New buy |
| 23 | ORIC | Oric Pharmaceuticals INC | — | EXIT | Sold out |
| 24 | VRCA | Verrica Pharmaceuticals INC | — | EXIT | Sold out |
| 25 | PEPG | Pepgen INC | — | NEW | New buy |
| 26 | TIL | Instil Bio INC | — | NEW | New buy |
| 27 | KRRO | Korro Bio INC | — | NEW | New buy |
| 28 | LOOP | Loop Industries INC | — | NEW | New buy |
| Period | Filed | Type | EDGAR |
|---|---|---|---|
| 2026-03-31 | 2026-05-15 | Amendment | View on EDGAR |
| 2026-03-31 | 2026-05-15 | 13F-HR | View on EDGAR |
| 2025-12-31 | 2026-02-13 | 13F-HR | View on EDGAR |
Institutions with a similar AUM
CIK 0002056069
Total reported value
$141.4M
14 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0001656167
Total reported value
$141.3M
240 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0001857588
Total reported value
$141.4M
60 stks
2026-03-31
AUM within 0.0% of this institution
Institutions with overlapping top holdings
CIK 0001144208
Total reported value
$155.9M
127 stks
2026-03-31
1 of the top 5 holdings overlap, including Alpha Architect 1-3 Mnth Box
CIK 0001388551
Total reported value
$4.0M
7 stks
2026-03-31
1 of the top 5 holdings overlap, including X4 Pharmaceuticals INC
CIK 0001441646
Total reported value
$168.5M
144 stks
2021-12-31
Stale — no recent filing
1 of the top 5 holdings overlap, including Relay Therapeutics INC